The UK Myeloma Forum (UKMF) is a collaborative organisation of healthcare professionals and scientists which aims to improve the treatment of patients with myeloma. The annual UKMF Scientific Workshop is an all-day event where leading experts share the latest biomedical research aiming to improve understanding of myeloma and develop new strategies to improve patient outcomes. This year’s…Details
OPTIMISING CURRENT TREATMENTS The number of drugs available as myeloma treatment has grown significantly over the last two decades with discovery and approval of immunomodulatory drugs (thalidomide, lenalidomide (Revlimid®) and pomalidomide (Imnovid®)), proteasome inhibitors (bortezomib (Velcade®), cafilzomib (Kyprolis®) and ixazomib (Ninlaro®)), histone deacetylase inhibitors (panobinostat) and monoclonal antibody drugs (daratumumab (Darzalex®) and elotuzumab (Empliciti®)). However,…Details
Speaker: Dr Andrew Chantry, Sheffield Teaching Hospitals NHS Foundation TrustDetails
Speaker: Mr Sean Molloy, Royal National Orthopaedic Hospital, LondonDetails
UKMF Autumn Day 2013: What do we know about myeloma in elderly patients from trials and observational studies?
Speaker: Prof Heinz Ludwig, Wilhelminenhospital, Vienna. AustriaDetails
Speaker: Dr Faith Davies, Royal Marsden Hospital and The Institute of Cancer Research, London.Details